|
Vol 49(2015) N 2 p. 312-321; DOI 10.1134/S0026893315020156  D. Wang1,2, J.X. Zhai3, L.M. Zhang4, D.W. Liu1*, X.H. Liu5 EPHX1 Tyr113His polymorphism contributes to hepatocellular carcinoma risk: evidence from a meta-analysis 1Department of Epidemiology and Biostatistics, School of Public Health, Hebei Medical University, Shijiazhuang, Hebei Province, 050017 China2Library, Hebei Medical University, Shijiazhuang, Hebei Province, 050017 China 3Department of Novelty Retrieval, Institute of Hebei Medical Information, Shijiazhuang, Hebei Province, 050071 China 4Division of Cardiology, Guanganmen Hospital, China Academy of Chinese Medical Science, Beijing, 100053 China 5Department of Occupational and Environmental Health, School of Public Health, Hebei Medical University, Shijiazhuang, Hebei Province, 050017 China *dwliu1956@hotmail.com Received - 2014-05-31; Accepted - 2014-06-26 To clarify the association between the microsomal epoxide hydrolase gene (EPHX1) Tyr113His polymorphism and the hepatocellular carcinoma (HCC) risk, a meta-analysis was performed. Through a literature search, 119 relevant records were identified, and 17 individual case-control studies from 13 publications were finally included, involving a total of 1480 HCC cases and 2564 controls. Overall, the EPHX1 Tyr113His polymorphism was associated with an increased risk of HCC. Subgroup analyses by the status of the Hardy-Weinberg equilibrium (HWE) in controls further confirmed this association. In subgroup analyses, increased associations were found in Asians, Caucasians, hepatitis B virus (HBV)-dominant areas, hepatitis C virus (HCV)-dominant areas, high and medium-rate areas of HCC, but not in Africans and low-rate areas of HCC, respectively. This meta-analysis suggests that EPHX1 Tyr113His polymorphism contributes to the HCC risk. EPHX1 Tyr113His, hepatocellular carcinoma, gene polymorphism, meta-analysis |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
